Four recently published Guidelines shed light on ANVISA's
procedures related to prior approval analysis of patent
applications
In November 2020, the Brazilian Health Surveillance Agency
(Brazilian FDA – "ANVISA") published four
guidelines disclosing the procedures adopted by ANVISA to analyze
prior approval of patent applications related to pharmaceutical
products and processes.
This is the first time ANVISA brings into view details on how
the Agency examines patent applications remitted by the Brazilian
Patent Office (BRPTO) for compliance with Article 229-C1 of the
Brazilian Patent Statute.
Since the agreement reached by ANVISA and the BRPTO in 2017
(Joint Ordinance 01/2017), ANVISA can only deny prior approval
based on public health matters. However, if the application relates
to therapeutic matters of interest for the Brazilian health
policies, ANVISA can perform a patentability analysis, which will
be considered by the BRPTO as a third-party observation